Dec. 13, 2013, 5:05 PM
- Stem Cell Therapeutics (SCTPF) raises $33M in gross proceeds through a private placement of 157.1M in common and preferred units (each with a 3/4 warrant to purchase an additional common share at $0.28) at a price of $0.21/unit.
- The round was led by a "prominent U.S. healthcare fund," with participation from 7 other funds.
- Funds will be used for IND-enabling studies, manufacturing, and phase I clinical trials of the company's CD47 cancer stem cell program.
Trillium Therapeutics Inc. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade... More
Other News & PR